Verrica Pharmaceuticals (VRCA) Debt to Equity (2021 - 2025)
Verrica Pharmaceuticals (VRCA) has 4 years of Debt to Equity data on record, last reported at -$0.73 in Q3 2025.
- For Q3 2025, Debt to Equity changed N/A year-over-year to -$0.73; the TTM value through Sep 2025 reached -$0.73, changed N/A, while the annual FY2024 figure was -$1.31, N/A changed from the prior year.
- Debt to Equity reached -$0.73 in Q3 2025 per VRCA's latest filing, down from -$0.72 in the prior quarter.
- Across five years, Debt to Equity topped out at $2.59 in Q2 2022 and bottomed at -$1.31 in Q4 2024.
- Average Debt to Equity over 4 years is $0.45, with a median of $0.72 recorded in 2021.
- The widest YoY moves for Debt to Equity: up 229.36% in 2022, down 151.13% in 2022.
- A 4-year view of Debt to Equity shows it stood at $1.28 in 2021, then surged by 102.5% to $2.59 in 2022, then plummeted by 150.67% to -$1.31 in 2024, then soared by 44.28% to -$0.73 in 2025.
- Per Business Quant database, its latest 3 readings for Debt to Equity were -$0.73 in Q3 2025, -$0.72 in Q2 2025, and -$0.69 in Q1 2025.